奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HALO 奥洛兹美医疗

未开盘 09-08 16:00:00 EDT

108.31

-1.88

-1.71%

盘后108.31

+0.000.00%

19:30 EDT

最高109.96	最低106.07	成交量162.56万
今开109.00	昨收110.19	日振幅3.53%
总市值122.93亿	流通市值121.31亿	总股本1.13亿
成交额1.76亿	换手率1.45%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HALO","market":"US","secType":"STK","nameCN":"奥洛兹美医疗","latestPrice":108.31,"timestamp":1788897600000,"preClose":110.19,"halted":0,"volume":1625633,"hourTrading":{"tag":"盘后","latestPrice":108.31,"preClose":108.31,"latestTime":"19:30 EDT","volume":52331,"amount":5667966.8,"timestamp":1788910200756,"change":0,"changeRate":0,"amplitude":0.000554},"delay":0,"changeRate":-0.01706143933206276,"floatShares":112000000,"shares":113498000,"eps":3.382141,"marketStatus":"未开盘","change":-1.88,"latestTime":"09-08 16:00:00 EDT","open":109,"high":109.961,"low":106.07,"amount":175892303.88791,"amplitude":0.035312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.382141,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788940800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1099285200000,"exchange":"NASDAQ","adjPreClose":110.19,"preHourTrading":{"tag":"盘前","latestPrice":109,"preClose":110.19,"latestTime":"09:29 EDT","volume":682,"amount":75108.2167,"timestamp":1788874170091,"change":-1.19,"changeRate":-0.0108,"amplitude":0.018967},"postHourTrading":{"tag":"盘后","latestPrice":108.31,"preClose":108.31,"latestTime":"19:30 EDT","volume":52331,"amount":5667966.8,"timestamp":1788910200756,"change":0,"changeRate":0,"amplitude":0.000554},"volumeRatio":1.185106,"impliedVol":0.3586,"impliedVolPercentile":0.388},"requestUrl":"/m/hq/s/HALO","defaultTab":"news","newsList":[{"id":"2658911935","title":"板块普涨之际 十只量化评分强劲的大盘医疗保健股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911935","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911935?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:27","pubTimestamp":1786462073,"startTime":"0","endTime":"0","summary":"经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。Centene Corporation以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics、Bright Spring Health Services紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics、Humana跻身前五，均获强烈“买入”评级。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303689","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0787776722.HKD","LU0128525929.USD","IE000M9KFDE8.USD","LU1323610961.USD","LU0154245673.USD","CNCG","LU1261432733.SGD","LU1074936037.SGD","LU1069347547.HKD","LU1732800096.USD","SOLV","CORT","IE00BJJMRX11.SGD","LU0345770993.USD","LU0079474960.USD","LU1718418525.SGD","SG9999018857.SGD","LU2244417387.USD","LU2242649171.HKD","NBIX","LU1201861249.SGD","SGXZ99366536.SGD","LU0097036916.USD","IE00B19Z8X17.USD","IE00B2B36J28.USD","LU0154245756.USD","LU1854103824.USD","LU1983260115.SGD","IE0004445015.USD","LU1506573853.SGD","IE0002270589.USD","LU2112291526.USD","LU0390134368.USD","BK4139","LU0795875086.SGD","LU2954938101.SGD","LU2125154935.USD","LU0353189680.USD","BTSG","SG9999014013.SGD","UNH","PSCH","LU1267930730.SGD","LU0187121727.USD","LU0238689110.USD","SG9999013999.USD","LU0456855351.SGD","HRTS","SG9999001176.USD","LU1003077747.HKD","LU1551013342.USD","SG9999014906.USD","IE00B775H168.HKD","IE00B19Z9505.USD","LU0162691827.USD","LU0130518102.USD","LU2089283258.USD","SG9999017495.SGD","LU0310800379.SGD","LU0672654240.SGD","LU2360032135.SGD","BK4533","IYH","LU0077335932.USD","LU0130102774.USD","LU2461242641.AUD","LU1066051498.USD","LU0912757837.SGD","LU0211326839.USD","SGXZ51526630.SGD","LU1699723380.USD","IE00BFSS7M15.SGD","LU1035773651.USD","SG9999002224.SGD","IE00B7SZLL34.SGD","LU0158827948.USD","PTH","LU0432979614.USD","LU0882574055.USD","LU2362541513.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1201861165.SGD","LU2133065610.SGD","LU0170899867.USD","LU0107464264.USD","LU1084165304.USD","LU2279689827.SGD","LU0053671581.USD","LU1674673428.USD","TMED","LU1989771016.USD","LU2028103732.USD","IE00BZ1G4Q59.USD","LU1778281490.HKD","LU1291159041.SGD","LU2361044865.SGD","LU1720051017.SGD","LU0943347566.SGD","LU2468319806.SGD","LU0310800965.SGD","LU0820561818.USD","LU0648000940.SGD","SG9999014914.USD","IE00B4JS1V06.HKD","BK4198","LU0708994859.HKD","CNC","LU1267930490.SGD","LU0345770308.USD","BK4196","IE00BFSS8Q28.SGD","LU0354030511.USD","LU0477156953.USD","LU0058720904.USD","LU0528227936.USD","VHT","LU2552382058.USD","LU0266013472.USD","LU1934455194.USD","LU0316494557.USD","LU2347655156.SGD","BK4534","LU0820562030.AUD","LU0648001328.SGD","LU1791710400.SGD","SG9999014880.SGD","LU1267930227.SGD","LU1061106388.HKD","TRUH","IE00B1XK9C88.USD","LU0130103400.USD","LU0496365809.HKD","LU1720051108.HKD","IE0004445239.USD","LU2125154778.USD","LU1037948541.HKD","IHF","FHLC","IE0002141913.USD","IE00B19Z3B42.SGD","BK4559","LU0708995401.HKD","LU0353189763.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4613","LU0143551892.USD","LU1854104046.USD","IE00BSNM7G36.USD","LU1066051225.USD","LU2065171402.SGD","LU2552382132.HKD","BK4585","LU1066051811.HKD","LU0859254822.USD","LU1267930573.SGD","LU0354030438.USD","LU0011850046.USD","LU1670627923.USD","LU0256863811.USD","LU2361044949.HKD","UNHG","LU0965509283.SGD","LGHT","LU0553294199.USD","LU1093756325.SGD","LU0109391861.USD","LU0795875169.SGD","LU0417517546.SGD","LU0052756011.USD","LU2023251221.USD","SG9999014005.SGD","LU0029864427.USD","HUM","LU0251132253.USD","LU0342679015.USD","BK4504","SGXZ57979304.SGD","LU1023059063.AUD","LU2087625088.SGD","LU2065171311.SGD","LU2491050154.USD","LU0072461881.USD","LU0211327993.USD","LU0980610538.SGD","IXJ","BK4581","LU0289739699.SGD","JDOC","HALO","LU0114720955.EUR","MHIP","IE00B894F039.SGD","LU0211326755.USD","SG9999014021.USD","LU2236285917.USD","LU2211815571.USD","LU0965509010.AUD","LU0094547139.USD","LU1548497426.USD","VEEV","IE00BWXC8680.SGD","LU0949170772.SGD","LU1791710582.SGD","LU0861579265.USD","LU0122379950.USD","IE00BKVL7J92.USD","SG9999014898.SGD","LU2357305700.SGD","BK4167","LU0203347892.USD","BK4588","LU2089984988.USD","LU0053666078.USD","SGXZ31699556.SGD","IE00B19Z8W00.USD","LU0823416689.USD","UNHW","LU0211328371.USD","LU1093756168.USD","LU1934455863.HKD","LU0661504455.SGD","BK4154","LU0557290698.USD","RXL","LU2264538146.SGD","LU2552382215.SGD","LU0310799852.SGD","LU2357627491.SGD","LU1934455277.USD","IE00BN29S564.USD","SG9999001176.SGD","IE00B3T34201.USD","LU1559883803.SGD","LU0130517989.USD","SG9999018865.SGD","LU0234572021.USD","LU2491050071.SGD","LU0965508806.USD","LU2089284900.SGD","LU1732799900.SGD","XLV","LU0048584097.USD","LU0738911758.USD","FFOX","LU0965509101.SGD","LU1814569148.SGD","IE00BKPKM429.USD","IE00BJT1NW94.SGD","LU1119994496.HKD","LU2362541273.HKD","LU0477156797.USD","LU0208291251.USD","LU2999663052.SGD","LU0128525689.USD","BK4532","LU0070302665.USD","LU1153585028.USD","LU0203345920.USD","GDOC","FBT","LU0320765489.SGD","IE00B19Z9Z06.USD","LU1670628061.USD","IE00BJJMRY28.SGD","LU0545039389.USD","LU2065170008.USD","LU1989764748.USD","LU0320765992.SGD","LU0149725797.USD","LU1914381329.SGD","FXH","LU0158827781.USD","SGXZ81514606.USD","LU2362540622.SGD","LU1989764664.SGD","BK4528","BK4566","EKG","LU1057294990.SGD","LU2324357040.USD","LU2361045086.USD","LU2491049909.HKD","LU1983299246.USD","DVA","IE00BZ9MQY76.HKD","LU1674673691.USD","LU0889565916.HKD","LU0198837287.USD","LU2111349929.HKD","IE00B19Z3581.USD","LU1496350502.SGD","LU0683600562.USD","LU2065169927.USD","LU1551013425.SGD","LU1988902786.USD","IE0034235188.USD","LU1037948897.HKD","LU0689472784.USD","LU0566484027.USD","LU2462591277.SGD","IE0005OL40V9.USD","LU1064131342.USD","LU0320765059.SGD","LU0109394709.USD","LU2271345857.HKD","IE00B7KXQ091.USD","SG9999002232.USD","LU0348723411.USD","IE00B1BXHZ80.USD","IE00B19Z9P08.USD","LU1066053197.SGD","BK4007","LU0820561909.HKD","LU0976567544.SGD","IE00BFXG1179.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129297985","title":"异动解读｜奥洛兹美医疗盘中上涨16.87%，Q2业绩大超预期叠加多家投行上调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1129297985","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129297985?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:14","pubTimestamp":1786119298,"startTime":"0","endTime":"0","summary":"8月8日，奥洛兹美医疗盘中上涨16.87%，报100.23美元/股，成交额3.79亿美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，营收指引上调至18.35亿至19.1亿美元，均显著高于市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197190040","title":"Leerink Partners上调奥洛兹美医疗评级至“跑赢大盘”，目标价从83美元升至110美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197190040","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197190040?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:05","pubTimestamp":1786100712,"startTime":"0","endTime":"0","summary":"Leerink Partners将奥洛兹美医疗（Halozyme Therapeutics）的股票评级从“与大盘持平”上调至“跑赢大盘”。与此同时，这家投行还将其目标股价从83美元大幅提升至110美元，较此前预测值高出约32.5%。这一调整反映出市场对该公司未来增长前景的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","HALO","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165993122","title":"异动解读｜奥洛兹美医疗盘前上涨5.38%，Q2业绩大超预期且全年指引大幅上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1165993122","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165993122?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:32","pubTimestamp":1786091553,"startTime":"0","endTime":"0","summary":"8月7日，奥洛兹美医疗盘前上涨5.38%，报90.9美元/股，成交额2634.59美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，全年营收指引上调至18.35亿至19.1亿美元，均显著高于此前指引及市场预期。强劲增长主要受ENHANZE技术平台特许权使用费持续放量驱动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥洛兹美医疗盘前上涨5.38%，Q2业绩大超预期且全年指引大幅上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125513225","title":"异动解读｜奥洛兹美医疗夜盘上涨6.08%，Q2业绩大超预期且全年指引大幅上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1125513225","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125513225?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:20","pubTimestamp":1786080031,"startTime":"0","endTime":"0","summary":"8月7日，奥洛兹美医疗夜盘上涨6.08%，报90.97美元/股，成交额2895.0美元。消息面上，公司发布第二季度财报，业绩全面大幅超出市场预期。Q2调整后每股收益2.28美元，远超分析师一致预期的1.84美元，同比增长48%；营收4.81亿美元，超预期约19%，同比增长47.7%。公司同时大幅上调全年指引，预计调整后每股收益8.65至9.00美元，全年营收指引上调至18.35亿至19.1亿美元，均显著高于市场预期的7.94美元及17.7亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥洛兹美医疗夜盘上涨6.08%，Q2业绩大超预期且全年指引大幅上调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655806134","title":"强生（JNJ）抗头颈癌药物获FDA优先审查 拓展适应症迎来关键节点","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806134","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655806134?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:43","pubTimestamp":1785422625,"startTime":"0","endTime":"0","summary":"凭借优先审评通道，FDA审查周期将缩短至6个月，常规审批时长为10个月，有望加速这款双靶点皮下制剂落地。若头颈癌适应症顺利获批，将进一步拓宽产品收入空间，同时利好合作方Halozyme。市场持续等待FDA最终审批结论，跟踪该药物在实体瘤领域持续拓展潜力。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2129689431.USD","LU2403377893.USD","LU0466842654.USD","LU1043141396.HKD","IE0001KFT4U8.USD","TRUH","BK4559","LU1162221912.USD","LU1032466523.USD","RXL","IE00B4R5TH58.HKD","FHLC","FTXH","LU1585245621.USD","LU2129689514.USD","LU1261432733.SGD","LU1894683264.USD","LU1043141123.HKD","IE00B1BXHZ80.USD","FFOX","BK4550","GDOC","HALO","IXJ","JDOC","BK4588","IE0034235303.USD","VHT","LU0203347892.USD","LABU","IE00BDGV0183.EUR","LU2592432038.USD","LU0689472784.USD","LU2129689605.HKD","XLV","BMED","IHE","LU0203345920.USD","JNJ","PJP","IE00BJJMRZ35.SGD","LU0994945656.USD","MEDX","LU1145028129.USD","LU2602419157.SGD","LU1032955483.USD","IYH","LU0098860793.USD","LU1280957306.USD","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168529165","title":"财报前瞻｜奥洛兹美医疗本季度营收预计增42.52%，回购计划或抬升每股收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1168529165","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168529165?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:34","pubTimestamp":1785382464,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗将于2026年08月06日美股盘后发布财报，本文梳理市场预测与关键看点。市场一致预期显示，本季度奥洛兹美医疗营收约为4.07亿美元，同比增长42.52%；调整后每股收益约为1.84美元，同比增长45.02%；息税前利润约为2.34亿美元，同比增长38.87%；目前未见对本季度毛利率与净利润或净利率的明确预测披露。上季度营收为3.77亿美元，同比增长42.23%；毛利率72.18%；归属于母公司股东的净利润为1.50亿美元，净利率39.83%；调整后每股收益为1.60美元，同比增长44.14%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜奥洛兹美医疗本季度营收预计增42.52%，回购计划或抬升每股收益","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152322","title":"Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152322","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652152322?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:59","pubTimestamp":1784552369,"startTime":"0","endTime":"0","summary":"双方将利用Halozyme专有的ENHANZE药物递送技术，共同推进Incyte旗下在研创新药INCA033989皮下注射剂型的开发。根据协议条款，Halozyme将从Incyte获得一笔首付款，并有资格在未来达成特定开发及商业化里程碑时获得追加付款。此外，Halozyme还将根据使用ENHANZE技术药物的未来净销售额抽取一定比例的特许权使用费。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IBBQ","INCY","BK4550","BK4588","LU0053671581.USD","159992","MEDX","06978","BK4139","BK1574","BK4585","IDNA","BK1161","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165004523","title":"奥洛兹美医疗与因塞特医疗达成全球合作与许可协议，利用Enhanze®技术开发皮下制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1165004523","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165004523?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:08","pubTimestamp":1784549338,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已与因塞特医疗签署了一项全球合作与许可协议。该协议旨在利用奥洛兹美医疗的Enhanze®技术，支持因塞特医疗旗下在研药物Inca033989开发皮下注射剂型。\n此次合作将结合双方的专业优势，探索通过皮下给药途径提升治疗便利性与患者体验的可能性。Enhanze®技术平台能够帮助大分子药物实现快速、高效的皮下递送。\n协议的达成标志着两家公司在创新药物递送解决方案领域的战略协同。此举有望为患者带来更便捷的治疗选择，并拓展相关技术的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4550","IDNA","BK4585","BK4588","LU0053671581.USD","HALO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168121593","title":"奥洛兹美医疗与因塞特医疗达成协议，授予其Mutcalr项目Enhanze技术开发权及两项额外靶点选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1168121593","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168121593?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:04","pubTimestamp":1784549047,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已授予生物制药公司因塞特医疗一项关键许可。根据协议，因塞特医疗将获得使用奥洛兹美医疗专有的Enhanze药物递送技术，以开发其Mutcalr项目的权利。此项合作不仅限于单一靶点，因塞特医疗同时还获得了两项额外靶点的选择权，为未来更广泛的管线开发铺平了道路。Enhanze技术旨在通过提高皮下给药的效率和便利性，优化生物制剂的给药方式。此次授权进一步拓展了Enhanze技术的应用范围，并强化了奥洛兹美医疗在合作开发领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IDNA","HALO","BK4532","LU0053671581.USD","BK4550","INCY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127536911","title":"奥洛兹美医疗任命大卫·拉姆齐为药物递送部门总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1127536911","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127536911?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:46","pubTimestamp":1783323960,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公司宣布，已任命大卫·拉姆齐担任其药物递送部门的总裁。这一人事任命旨在加强公司在药物递送技术领域的领导与战略执行能力。拉姆齐将负责推动该部门的创新与业务发展，助力公司拓展其技术平台的应用范围。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643731104","title":"HALO交易回归？政策引爆稀土，千亿龙头两连板！","url":"https://stock-news.laohu8.com/highlight/detail?id=2643731104","media":"格隆汇","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643731104?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:00","pubTimestamp":1781593207,"startTime":"0","endTime":"0","summary":"战略资源迎价值重估","market":"sg","thumbnail":"https://img3.gelonghui.com/1ece2-a56a49c4-985e-467f-8dbc-f2536c046453.jpg?guru_height=718&guru_width=1280&guru_size=200505","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1ece2-a56a49c4-985e-467f-8dbc-f2536c046453.jpg?guru_height=718&guru_width=1280&guru_size=200505"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5223104","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["600549","BK0155","LU2187417386.USD","BK1116","BK0028","LU0053671581.USD","BK0233","BK0010","159715","000970","06680","BK0125","BK0076","600392","BK4139","HALO","BK0086","002645","BK0188","BK0077","LU2351347302.SGD","LU2929501877.USD","BK0070","000831","BK0138","600206","BK0182","BK0251","BK0006","BK0214","BK0102","BK0235","603663","BK0105","REMX","BK0084","600366","SETM","BK0122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172758013","title":"奥洛兹美医疗确认：基于新发布的2029年IPAY医保药品价格谈判计划拟议规则草案，预计至迟2035年前特许权使用费收入影响为零或极小","url":"https://stock-news.laohu8.com/highlight/detail?id=1172758013","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172758013?lang=zh_cn&edition=full","pubTime":"2026-06-15 18:04","pubTimestamp":1781517861,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公司已正式确认，根据最新发布的、针对2029年IPAY计划的医保药品价格谈判计划拟议规则草案，公司预计其特许权使用费收入至少在2035年之前不会受到显著影响，影响程度预计为零或极小。这一评估为投资者提供了关于公司长期收入前景的明确指引，缓解了市场对潜在政策变动可能冲击其核心收入流的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637788303","title":"国金证券：新一轮HALO交易或本轮行情终结 取决于霍尔木兹海峡 建议关注原油供需格局变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2637788303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637788303?lang=zh_cn&edition=full","pubTime":"2026-05-24 18:48","pubTimestamp":1779619738,"startTime":"0","endTime":"0","summary":"如果当霍尔木兹海峡重新通航，景气扩散与经济修复将是全球顺周期资产与实物资产的最强共振，新一轮HALO交易或在到来；如果海峡持续关闭最终导致货币政策变化，则是全球风险资产反弹的终结。霍尔木兹海峡流量恢复较为缓慢，全球供应链压力不断攀升，并正在向制造业进行传导。美联储的货币政策闸门和霍尔木兹海峡的闸门，将在6月形成交汇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DWT","USO","USE","FTXN","GUSH","IEO","BK4139","DBO","QMmain","USOI","DIG","DBC","ERX","USL","VDE","600109","BK0201","HALO","WTIU","CLmain","SCO","BNO","BZmain","PXJ","BK0012","OIH","UCO","UGA","XES","BK4585","DUG","DBE","BK0028","OILT","BK0183","MCLmain","OILK","BK4570","BK0276","OILU","DDG","PXE","BK0188","BK4588","XOP","IXC","DRIP","LU0053671581.USD","DRLL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197570760","title":"异动解读 | 奥洛兹美医疗宣布10亿美元股票回购计划，盘中大涨7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197570760","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197570760?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:22","pubTimestamp":1778595760,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（HALO）今日盘中股价大幅上涨7.71%，引起了市场的广泛关注。消息面上，奥洛兹美医疗公司宣布了一项总额高达10亿美元的股票回购计划，根据该计划，公司预计在2026年将至少回购价值4亿美元的股票。大规模的股票回购通常被视为公司对自身未来前景充满信心的信号，有助于减少流通股数量并可能提升每股收益，从而提振股价。此次股票回购计划的宣布，直接推动了奥洛兹美医疗股价在交易时段的强劲表现，显示出投资者对该举措的积极反应和对公司价值的认可。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191310498","title":"异动解读 | 奥洛兹美医疗宣布10亿美元股票回购计划，盘前大涨6.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191310498","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191310498?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:18","pubTimestamp":1778573882,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（HALO）今日盘前股价大幅上涨6.91%，引起了市场的广泛关注。消息面上，奥洛兹美医疗公司宣布了一项总额高达10亿美元的股票回购计划，根据该计划，公司预计在2026年将至少回购价值4亿美元的股票。大规模的股票回购通常被视为公司对自身未来前景充满信心的信号，有助于减少流通股数量并可能提升每股收益，从而提振股价。此次股票回购计划的宣布，直接推动了奥洛兹美医疗股价在盘前交易时段走强，显示出投资者对该举措的积极反应。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118542769","title":"奥洛兹美医疗宣布10亿美元股票回购计划，2026年将至少回购4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118542769","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118542769?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:20","pubTimestamp":1778530833,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公司宣布了一项总额高达10亿美元的股票回购计划。根据该计划，公司预计在2026年将至少回购价值4亿美元的股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127510300","title":"葛兰素史克将支付首付款及里程碑款项，奥洛兹美医疗享有销售分成权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1127510300","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127510300?lang=zh_cn&edition=full","pubTime":"2026-05-07 21:03","pubTimestamp":1778159035,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics）宣布与葛兰素史克（GSK）达成合作协议，后者将向其支付首付款及后续里程碑款项。根据协议条款，奥洛兹美医疗还将获得基于产品销售额的版权分成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0545562505.USD","IE00BWDBJ516.SGD","BK4139","LU0225771236.USD","LU1670756490.USD","LU1064927863.SGD","LU1228905540.USD","SG9999001176.USD","LU1400636491.USD","LU1400636574.HKD","LU0306807586.USD","LU0161305163.EUR","LU0058720904.USD","LU2089984988.USD","BK5011","LU0985481810.HKD","LU0225283273.USD","IE00B3T34201.USD","SG9999013999.USD","LU1015430645.USD","LU0971552830.HKD","LU1228905037.USD","SGXZ57979304.SGD","IE0034235071.USD","LU1046248800.SGD","IE00BQJZX424.USD","LU1481599808.USD","LU1481600234.SGD","LU1983299246.USD","LU1202635105.USD","LU0321505439.SGD","LU0109981661.USD","LU1309081286.SGD","LU0557290698.USD","LU0203345920.USD","LU1487256676.USD","LU2468319806.SGD","LU2646069778.SGD","LU0306806265.USD","GSK.UK","LU0575583348.USD","LU1302929846.USD","SG9999001176.SGD","LU1035777561.USD","LU1645745479.HKD","LU1400636657.SGD","LU1098665638.USD","LU0203347892.USD","LU0211331839.USD","LU0971552673.USD","LU0225284248.USD","LU0987226296.USD","HALO","LU0289739699.SGD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143992348","title":"奥洛兹美医疗与葛兰素史克达成全球合作与许可协议 共同开发多款潜力肿瘤靶向药物的皮下制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1143992348","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143992348?lang=zh_cn&edition=full","pubTime":"2026-05-07 21:01","pubTimestamp":1778158879,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布与跨国制药巨头葛兰素史克签署一项全球合作与许可协议，双方将基于奥洛兹美医疗专有的药物输送技术平台，为葛兰素史克研发管线中多个前景广阔的肿瘤靶向疗法开发皮下注射制剂。此项合作旨在通过创新的给药方式，提升患者用药的便捷性与治疗体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163450928","title":"奥洛兹美医疗与欧如卡达成全球合作与授权协议，将利用Hypercon™技术共同开发Orka-001","url":"https://stock-news.laohu8.com/highlight/detail?id=1163450928","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163450928?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:01","pubTimestamp":1778068882,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗与欧如卡公司联合宣布，双方已签署一项全球性的合作与授权协议。该协议的核心内容，是围绕利用奥洛兹美医疗专有的Hypercon™药物递送技术，共同推进欧如卡旗下在研药物Orka-001的开发工作。此次合作旨在结合双方在技术平台与药物研发领域的专长，加速创新疗法的问世。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.halozyme.com","stockEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0503},{"period":"3month","weight":0.5363},{"period":"6month","weight":0.7041},{"period":"1year","weight":0.4279},{"period":"ytd","weight":0.6094}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Halozyme Therapeutics, Inc.成立于1998年，于2007年11月从内华达州重新注册成立于特拉华州，是一家生物制药公司，专注于开发可改善患者护理的创新疗法并将其商业化。该公司的研究以细胞外基质为中心，围绕细胞的结构网络在组织完整性、细胞信号传导、迁移和存活中起着至关重要的作用。凭借多年研究积累的广泛专业知识，Halozyme利用其对ECM的深刻科学理解，开发针对这一复杂且生物丰富的环境的新型治疗方法和药物递送技术，旨在推进下一代治疗解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005218},{"month":2,"riseRate":0.590909,"avgChangeRate":0.022787},{"month":3,"riseRate":0.5,"avgChangeRate":0.038012},{"month":4,"riseRate":0.565217,"avgChangeRate":-0.006814},{"month":5,"riseRate":0.565217,"avgChangeRate":0.006828},{"month":6,"riseRate":0.608696,"avgChangeRate":0.049475},{"month":7,"riseRate":0.652174,"avgChangeRate":0.035849},{"month":8,"riseRate":0.521739,"avgChangeRate":0.007316},{"month":9,"riseRate":0.391304,"avgChangeRate":0.020072},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.027834},{"month":11,"riseRate":0.636364,"avgChangeRate":0.065813},{"month":12,"riseRate":0.545455,"avgChangeRate":0.110354}],"exchange":"NASDAQ","name":"奥洛兹美医疗","nameEN":"Halozyme Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥洛兹美医疗,HALO,奥洛兹美医疗股票,奥洛兹美医疗股票老虎,奥洛兹美医疗股票老虎国际,奥洛兹美医疗行情,奥洛兹美医疗股票行情,奥洛兹美医疗股价,奥洛兹美医疗股市,奥洛兹美医疗股票价格,奥洛兹美医疗股票交易,奥洛兹美医疗股票购买,奥洛兹美医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}